SpyGlass Pharma, Inc. Common Stock
Market Cap
610M
Short interest (May 15)
2.6%
Net Short (Jun 03 ): 0.0%
Borrow Fee
4.54%
↓ 41.4%
Available Shares
50K
↓ 34.8%
Price Chart
Company Overview
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.